PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 12, 2016JAMA Oncology179 citationsOpen Access

Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression

SGSaby GeorgeRoswell Park Comprehensive Cancer Center
Robert J. Motzer
Robert J. MotzerUniversité Claude Bernard Lyon 1HHHans J. HammersSouthwestern Medical Center

Key Points

Key points are not available for this paper at this time.

Abstract

clinicaltrials.gov Identifier: NCT01354431.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

George et al. (2016) studied this question.

synapsesocial.com/papers/69d81290617ce96c42ae2e00https://doi.org/10.1001/jamaoncol.2016.0775
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma2015 · 5,952 citations
  2. 2The National Comprehensive Cancer Network1998 · 16,882 citations
  3. 3Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma2007 · 3,665 citations
  4. 4Nonparametric Estimation from Incomplete Observations1992 · 45,552 citations
  5. 5Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab2023 · 234 citations